000			02269nam a22004335i 4500
001			978-1-4614-1662-3
003			DE-He213
005			20140220083243.0
007			cr nn 008mamaa
008			111012s2012 xxu| s |||| 0|eng d
020			_a9781461416623 _9978-1-4614-1662-3
024	7		_a10.1007/978-1-4614-1662-3 _2doi
050		4	_aR-RZ
072		7	_aMBGR _2bicssc
072		7	_aMED000000 _2bisacsh
082	0	4	_a610 _223
100	1		_aTurner, J. Rick. _eauthor.
245	1	0	_aKey Statistical Concepts in Clinical Trials for Pharma _h[electronic resource] / _cby J. Rick Turner.
264		1	_aNew York, NY : _bSpringer New York, _c2012.
300			_aIX, 61p. 1 illus. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aSpringerBriefs in Pharmaceutical Science & Drug Development, _x1864-8118
520			_aThis Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.
650		0	_aMedicine.
650		0	_aPharmaceutical technology.
650	1	4	_aBiomedicine.
650	2	4	_aBiomedicine general.
650	2	4	_aPharmaceutical Sciences/Technology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781461416616
830		0	_aSpringerBriefs in Pharmaceutical Science & Drug Development, _x1864-8118
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-4614-1662-3
912			_aZDB-2-SBL
999			_c101111 _d101111